Please assess the completion status of the following clinical trial:

Trial Title: B-Lymphocyte Immunotherapy in Islet Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Mentally stable and able to comply with study procedures~* Clinical history compatible with type 1 diabetes with onset at less than 40 years of age, insulin dependence for at least 5 years at study entry, and a sum of age and insulin dependent diabetes duration of at least 28~* Absent stimulated C-peptide (less than 0.3 ng/ml) 60 and 90 minutes post-mixed-meal tolerance test~* Involvement of intensive diabetes management, defined as:~  1. Self-monitoring of glucose values no less than a mean of three times each day averaged over each week~ 2. Administration of three or more insulin injections each day or insulin pump therapy~* Under the direction of an endocrinologist, diabetologist, or diabetes specialist with at least three evaluations the 12 months prior to study enrollment~* At least one episode of severe hypoglycemia in the past 12 months, defined as an event with one of the following symptoms: memory loss; confusion; uncontrollable behavior; irrational behavior; unusual difficulty in awakening; suspected seizure; seizure; loss of consciousness; or visual symptoms in which the participant was unable to treat him/herself and which was associated with either a blood glucose (BG) level \< 54 mg/dL \[3.0 mmol/L\] or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, in the past 12 months prior to study enrollment~* Reduced awareness of hypoglycemia. More information about this criterion, including specific definition of hypoglycemia unawareness, is in the protocol.~Exclusion Criteria:~* Body mass index (BMI) greater than 30 kg/m2 or weight less than or equal to 50 kg~* Insulin requirement of more than 1.0 IU/kg/day or less than 15 U/day~* HbA1c greater than 10%~* Untreated proliferative diabetic retinopathy~* Systolic blood pressure higher than 160 mmHg or diastolic blood pressure higher than 100 mmHg~* Measured glomerular filtration rate using iohexol of less than 80 ml/min/1.73m2. More information about this criterion is in the protocol.~* Presence or history of macroalbuminuria (greater than 300 mg/g creatinine)~* Presence or history of panel-reactive anti-HLA antibody levels greater than 20% by flow cytometry. More information about this criterion is in the protocol.~* Pregnant, breastfeeding, or unwilling to use effective contraception throughout the study and 4 months after study completion~* Active infection, including hepatitis B, hepatitis C, HIV, or tuberculosis. More information about this criterion is in the protocol.~* Negative for Epstein-Barr virus by IgG determination~* Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection within one year prior to study enrollment~* History of malignancy except for completely resected squamous or basal cell carcinoma of the skin~* Known active alcohol or substance abuse~* Baseline Hgb below the lower limits of normal, lymphopenia, neutropenia, or thrombocytopenia~* History of Factor V deficiency~* Any coagulopathy or medical condition requiring long-term anticoagulant therapy after transplantation or individuals with an INR greater than 1.5~* Severe coexisting cardiac disease, characterized by any one of the following conditions:~  1. Heart attack within the last 6 months~ 2. Evidence of ischemia on functional heart exam within the year prior to study entry~ 3. Left ventricular ejection fraction less than 30%~* Persistent elevation of liver function tests at the time of study entry~* Symptomatic cholecystolithiasis~* Acute or chronic pancreatitis~* Symptomatic peptic ulcer disease~* Severe unremitting diarrhea, vomiting, or other gastrointestinal disorders that could interfere with the ability to absorb oral medications~* Hyperlipidemia despite medical therapy (fasting LDL cholesterol greater than 130 mg/dl, treated or untreated; and/or fasting triglycerides greater than 200 mg/dl)~* Receiving treatment for a medical condition that requires chronic use of systemic steroids, except the use of 5 mg or less of prednisone daily, or an equivalent dose of hydrocortisone, for physiological replacement only~* Treatment with antidiabetic medication other than insulin within the past 4 weeks~* Use of any investigational agents within the past 4 weeks~* Received a live attenuated vaccine(s) within 2 months of study entry~* Any medical condition that, in the opinion of the investigator, will interfere with safe participation in the trial~* Treatment with any immunosuppressive regimen at the time of enrollment~* A previous islet transplant~* A previous pancreas transplant, unless the graft failed within the first week due to thrombosis, followed by pancreatectomy and transplant occurred more than 6 months prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Allogeneic Pancreatic Islet Cells (Type: EXPERIMENTAL): Participants will receive up to three islet transplants and maintenance immunosuppressive therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy